“This new group is expected to focus on both product lines, VIVO and LockeT”, continued CEO David Jenkins. “Over the last year, we have been primarily working on getting VIVO into key accounts and accumulating clinical data on LockeT. This expansion demonstrates a new effort toward commercialization of both product lines. With a 90% gross margin on both products, we anticipate that the expected increase in revenue will bring about cash flow break even by the end of this calendar year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision Q4 revenue $128,800 vs. $0 last year
- Catheter Precision to sponsor Monaco USA Arrhythmia Course
- Catheter Precision announces first use of VIVO in Qatar
- Catheter Precision announces first use of LockeT outside of U.S.
- Catheter Precision announces first use of VIVO with pediatric patient
